Oruka Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 7.43M | $364.51M | 0.02% | Added+2.3% | 2026-03-31 |
| Viking | long/short | 2.67M | $130.80M | 0.37% | Unchanged | 2026-03-31 |
| StateStreet | passive | 1.61M | $79.14M | 0.00% | Added+16.6% | 2026-03-31 |
| Wellington | fundamental | 121.2K | $5.95M | 0.00% | Added+43.1% | 2026-03-31 |
| TwoSigma | quant | 19.4K | $949.80K | 0.00% | Trimmed-32.2% | 2026-03-31 |
| TRowePrice | fundamental | 727.4K | $35.68K | 0.00% | Added+12.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.50 | — | — |
| 2026-05-13 | -0.54 | -0.48 | +11.58% |
| 2026-03-12 | -0.62 | -0.45 | +26.89% |
| 2025-11-12 | -0.52 | -0.55 | -4.96% |
| 2025-08-11 | -0.43 | -0.46 | -6.36% |
| 2025-05-14 | -0.47 | -0.40 | +15.79% |
| 2025-03-06 | -0.41 | -0.49 | -18.55% |
| 2024-11-13 | -0.38 | -1.46 | -280.21% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ORKA | -6.47% | +78.23% | +93.10% | +434.03% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -9.44% | +82.87% | +96.55% | +421.34% |